Abstract
The study aimed to compare the effectiveness of low-molecular-weight heparins (LMWH) followed by Rivaroxaban with no anticoagulant treatment in preventing deep vein thrombosis (DVT) after open reduction and internal fixation surgery (ORIF) for posterior cruciate ligament (PCL) avulsion fractures. This quasi-experimental study enrolled 37 patients with posterior cruciate ligament (PCL) avulsion fractures. Following surgery, four patients were excluded for not meeting the inclusion criteria, and the remaining 33 participants were allocated into Group A (n = 16) and Group B (n = 17). Surgical methods involved standard open reduction and internal fixation surgery (ORIF) protocols and anatomical alignment restoration using absorbable Bone Anchor Nails. Group A received prophylactic anticoagulation with LMWH followed by Rivaroxaban, while Group B did not received any anticoagulant. All patients received standard postoperative care included standardized rehabilitation protocols and monitoring for DVT using Color Doppler Ultrasound examinations. Patients underwent follow-up ultrasound examinations at 7 days and 1-month post-operation to assess DVT presence and condition. This comprehensive methodology allows for a thorough evaluation of the efficacy and safety of prophylactic anticoagulation in patients with PCL avulsion fractures and complications were observed between the two groups. The study included 33 patients who had undergone surgical treatment for PCL avulsion fractures, divided into Group A (LMWH followed by Rivaroxaban) and Group B (No anticoagulant treatment). No statistically significant differences were observed in the demographic and preoperative laboratory data between Group A (LMWH followed by Rivaroxaban) and Group B (no anticoagulation). Postoperatively, ESR, CRP, ALB, and Hb levels showed no significant differences between the two groups (P > 0.05). At 1 month postoperatively, the overall incidence of DVT was significantly lower in Group A (6.25%) than in Group B (35.29%) (P = 0.041). The percentage of DVT-free patients was 93.75% in Group A and 64.71% in Group B (P = 0.041). During the first seven postoperative days, the DVT incidence was 6.25% in Group A and 17.65% in Group B (P = 0.316), with a higher percentage of DVT-free patients in Group A (P = 0.041). From day 8 to 1 month postoperatively, no DVT cases were detected in Group A, while the incidence in Group B was 21.43% (P < 0.01). LMWH followed by Rivaroxaban significantly reduced DVT after PCL avulsion surgery. In addition, the D-D levels postoperatively were lower in the group of LMWH followed by Rivaroxaban group at 7 and 10 days after the operation. As for other inflammatory markers, there was no significant difference between the two groups. The reduction in DVT risk and D-Dimer levels suggests that the LMWH-rivaroxaban regimen may offer a clinically beneficial approach to anticoagulation therapy in patients undergoing PCL avulsion surgery.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- ALB :
-
Albumin
- BMI:
-
Body mass index
- CRP:
-
C-reactive protein
- D-D:
-
D-dimer
- DVT:
-
Deep vein thrombosis
- ESR:
-
Erythrocyte sedimentation rate
- Hb:
-
Hemoglobin
- LMWH:
-
Low molecular weight heparin
- MCVT:
-
Muscular calf vein thrombosis
- NSAIDs:
-
Nonsteroidal anti-inflammatory drugs
- ORIF:
-
Open reduction and internal fixation
- PCL:
-
Posterior cruciate ligament
- PE:
-
Pulmonary embolism
- PPIs:
-
Proton pump inhibitors
- PTVT:
-
Popliteal vein thrombosis
- SD:
-
Standard deviation
- VTE:
-
Venous thromboembolism
- HIT:
-
Heparin-induced thrombocytopenia
- UFH:
-
Unfractionated heparin
- VKAs:
-
Vitamin K antagonists
- INR:
-
International normalized ratio
- DOACs:
-
Direct oral anticoagulants
References
Stone, J. et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc. Diagn. Ther. 7, S276–S284 (2017).
Stubbs, M. J., Mouyis, M. & Thomas, M. Deep vein thrombosis. BMJ 360, k351 (2018).
Kabashneh, S., Singh, V. & Alkassis, S. A Comprehensive literature review on the management of distal deep vein thrombosis. Cureus 12, e8048.
Heestermans, M. et al. A short history, their mechanism of action, pharmacology, and indications. Cells 11, 3214 (2022).
Mulloy, B., Hogwood, J., Gray, E., Lever, R. & Page, C. P. Pharmacology of heparin and related drugs. Pharmacol. Rev. 68, 76–141 (2016).
Orfeo, T., Butenas, S., Brummel-Ziedins, K. E., Gissel, M. & Mann, K. G. Anticoagulation by factor Xa inhibitors. J. Thromb. Haemost. 8, 1745–1753 (2010).
Comin, J. & Kallmes, D. F. Dabigatran (Pradaxa). AJNR Am. J. Neuroradiol. 33, 426–428 (2012).
Wu, S. et al. Warfarin and vitamin K epoxide reductase: A molecular accounting for observed Inhibition. Blood 132, 647–657 (2018).
Fa, O., Al, G. M. & Ma, B. C., J, H. Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thrombosis Res 28 (1982).
Davidson, S., Pogorzelski, N., Dowd, T. C. & Huh, J. Incidence of deep vein thrombosis (DVT) in patients using a knee scooter. Foot Ankle Orthop. 7, 2473011421S00172 (2022).
Itou, J., Kuwashima, U., Itoh, M. & Okazaki, K. No difference in the incidence or location of deep venous thrombosis according to use of pharmacological prophylaxis following total knee arthroplasty. BMC Musculoskelet. Disord. 22, 819 (2021).
Bandeira, F. C. V., Pitta, G. B. B., Castro, A. A. & Miranda, F. Postoperative incidence of deep vein thrombosis after major lower extremity amputation. Int. Angiol. 27, 489–493 (2008).
Velmahos, G. C. et al. Inability of an aggressive policy of thromboprophylaxis to prevent deep venous thrombosis (DVT) in critically injured patients: Are current methods of DVT prophylaxis insufficient? J. Am. Coll. Surg. 187, 529–533 (1998).
X, X. & B, C. Preoperative risk factors for deep vein thrombosis in knee osteoarthritis patients undergoing total knee arthroplasty. J.Orthop. Sci.: Offi. J. Jpn. Orthop. Assoc. 28, (2023).
Qiao, L. et al. Identifying high-risk groups for deep vein thrombosis after primary total knee arthroplasty using preoperative Caprini scores and D-dimer levels. J. Orthop. Surg. Res. 19, 616 (2024).
Acuña, A. J., Grits, D., Samuel, L. T., Emara, A. K. & Kamath, A. F. Perioperative blood transfusions are associated with a higher incidence of thromboembolic events after TKA: An analysis of 333,463 TKAs. Clin. Orthop. Relat. Res. 479, 589–600 (2021).
Stringer, M. D. et al. Deep vein thrombosis after elective knee surgery. An incidence study in 312 patients. J. Bone Joint Surg. Br. 71, 492–497 (1989).
Januel, J. M. et al. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: A systematic review. JAMA 307, 294–303 (2012).
Maletis, G. B., Inacio, M. C. S., Reynolds, S. & Funahashi, T. T. Incidence of symptomatic venous thromboembolism after elective knee arthroscopy. J. Bone Joint Surg. Am. 94, 714–720 (2012).
Sonin, A. H. et al. Posterior cruciate ligament injury: MR imaging diagnosis and patterns of injury. Radiology 190, 455–458 (1994).
Ej, A. K., Ka, S. & Mj, A. C. Posterior Cruciate Ligament Avulsion Fractures. Curr. Rev. Musculoskelet. Med 11 (2018).
Liu, H. et al. Outcomes of tibial avulsion fracture of the posterior cruciate ligament treated with a homemade Hook plate. Injury 52, 1934–1938 (2021).
Ali Hasan, M., Azeez Alsaadi, M. & Tahseen Mehsen, J. Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: A retrospective study. Int. J. Clin. Pract. 75, e14552 (2021).
The effect. Of anticoagulants on venous thrombosis prevention after knee arthroscopy: A systematic review. Int. Orthop. 43, 2303–2308 (2019).
Rivaroxaban versus enoxaparin for the. Prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis. Medicine 97, (2018).
Fox, A. J. S., Wanivenhaus, F., Burge, A. J., Warren, R. F. & Rodeo, S. A. The human meniscus: a review of anatomy, function, injury, and advances in treatment. Clin. Anat. 28, 269–287 (2015).
Ye, S. et al. The incidence of deep venous thrombosis after arthroscopically assisted anterior cruciate ligament reconstruction. Arthroscopy 29, 742–747 (2013).
Hill, J. & Treasure, T. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients having surgery: summary of NICE guidance. BMJ 334, 1053–1054 (2007).
Hirsh, J. Low-molecular-weight heparin: A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation 98, 1575–1582 (1998).
Junqueira, D. R. G., Perini, E., Penholati, R. R. M. & Carvalho, M. G. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst. Rev. CD007557 https://doi.org/10.1002/14651858.CD007557.pub2 (2012).
Argandykov, D. et al. Low-molecular-weight heparin is superior to unfractionated heparin in Lowering the risk of venous thromboembolism after traumatic lower extremity amputation. Surgery 174, 1026–1033 (2023).
Lui, A. et al. Safety and comparative efficacy of initiating low-molecular-weight heparin within 24 hours of injury or surgery for venous thromboembolism prophylaxis in patients with spinal cord injury: a prospective TRACK-SCI registry study. Neurosurg. Focus. 55, E17 (2023).
van der Hulle, T. et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: A systematic review and meta-analysis. J. Thromb. Haemost. 12, 320–328 (2014).
Lazo-Langner, A., Fleet, J. L., McArthur, E. & Garg, A. X. Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study. J. Thromb. Haemost. 12, 1626–1635 (2014).
Folsom, A. R., Lutsey, P. L., Heckbert, S. R. & Cushman, M. Serum albumin and risk of venous thromboembolism. Thromb. Haemost. 104, 100 (2010).
Eichinger, S. et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 290, 1071–1074 (2003).
Samama, M. M. et al. D-dimer levels, constitutional thrombophilia, and venous thrombosis prediction: clinical aspects and implications. Semin Vasc Med. 5, 371–374 (2005).
Peng, H. et al. Predictive nomogram for postoperative lower-limb deep vein thrombosis in patients undergoing endoscopic endonasal surgery during hospitalization: A retrospective cohort study. Sci. Rep. 15, 3221 (2025).
Swanson, E. Doppler ultrasound imaging for detection of deep vein thrombosis in plastic surgery outpatients: A prospective controlled study. Aesthet. Surg. J. 35, 204–214 (2015).
Rm, M., Rd, B., Cv, D., Lk, J. & P, W. Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: The Safe, simple transitions (SST) study. Thromb. Res. 130, (2012).
J, B.-W. et al. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or Rivaroxaban in hip and knee replacement surgery: Findings from the ORTHO-TEP registry. Thromb. Haemost. 109, (2013).
Nemeth, B. & Cannegieter, S. C. Venous thrombosis following lower-leg cast immobilization and knee arthroscopy: from a population-based approach to individualized therapy. Thromb. Res. 174, 62–75 (2019).
Katsman, A., Strauss, E. J., Campbell, K. A. & Alaia, M. J. Posterior cruciate ligament avulsion fractures. Curr. Rev. Musculoskelet. Med. 11, 503–509 (2018).
Nakamura, M. et al. Spinal anesthesia increases the risk of venous thromboembolism in total arthroplasty. Med. (Baltim). 96, e6748 (2017).
Hernandez, A. J., de Almeida, A. M., Fávaro, E. & Sguizzato, G. T. The influence of tourniquet use and operative time on the incidence of deep vein thrombosis in total knee arthroplasty. Clin. (Sao Paulo) 67, 1053–1057 (2012).
Acknowledgements
We would like to express our gratitude to Prof. Zhang Xiaoli, Prof. Liu Yajie, Prof. Qu Fanwei, Prof. Zhu Youbao, Miss Xie Haiping, Miss Wang Yue, Miss Pu Hui, Miss Cheng Yu, Miss Zhang Zilei and all the teachers from the International Education School at Kunming Medical University for their care and support.
Funding
1. Spring City Plan: The High-level Talent Promotion and Training Project of Kunming Yunnan Revitalization Talent Support Programme Young Talent Project (2024SCP001). 2. Applied Basic Research Foundation of Yunnan Province and Kunming Medical University (202201AY070001-194). 3. Kunming Health Commission Health Science and Technology Talent Project (2021-SW-14). 4. Applied Basic Research Foundation of Yunnan Province (202301AU070104). Applied Basic Research Foundation of Yunnan Province and Kunming Medical University (202301AY070001-180). 5. Kunming Health Commission Health Science and Technology Talent Project (2023-SW-65).
Author information
Authors and Affiliations
Contributions
Z.C., Z.W., and M.M.M. designed this study. M.M.M., Y.X., T.-H.W., and J.H. conducted this study. H.Y., H.L., and Z.Y., J.W. collected the data. R.H. and J.X. analyzed the data. M.M.M. and Z.C. and M.A.H. wrote the manuscript.All authors contributed to the final approval of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethical approval
The ethical approval granted by the Yan’An Hospital Affiliated to Kunming Medical University Medical Ethics Committee (Ethical Approval Number: 2024-043-01), Kunming, Yunnan, China.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Mithu, M.M., Wang, TH., Huang, J. et al. Deep vein thrombosis incidence after sequential Low-molecular-weight heparin and Rivaroxaban versus no prophylaxis in posterior cruciate ligament avulsion fractures. Sci Rep (2026). https://doi.org/10.1038/s41598-025-18884-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-025-18884-0